HU226244B1 - Gyógyszer-kombináció a diabétesz megelõzésére vagy kezelésére - Google Patents
Gyógyszer-kombináció a diabétesz megelõzésére vagy kezelésére Download PDFInfo
- Publication number
- HU226244B1 HU226244B1 HU0202204A HUP0202204A HU226244B1 HU 226244 B1 HU226244 B1 HU 226244B1 HU 0202204 A HU0202204 A HU 0202204A HU P0202204 A HUP0202204 A HU P0202204A HU 226244 B1 HU226244 B1 HU 226244B1
- Authority
- HU
- Hungary
- Prior art keywords
- insulin
- alkyl
- antidiabetic
- hydroxy
- piperidino
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 15
- 206010012601 diabetes mellitus Diseases 0.000 title description 5
- 238000011321 prophylaxis Methods 0.000 title description 3
- 239000002253 acid Substances 0.000 claims abstract description 18
- 239000003472 antidiabetic agent Substances 0.000 claims abstract description 16
- 230000003178 anti-diabetic effect Effects 0.000 claims abstract description 14
- 239000003524 antilipemic agent Substances 0.000 claims abstract description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 37
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 21
- 102000004877 Insulin Human genes 0.000 claims description 19
- 108090001061 Insulin Proteins 0.000 claims description 19
- 229940125396 insulin Drugs 0.000 claims description 19
- LEAWDHURBAHMCQ-UHFFFAOYSA-N (2-hydroxy-3-piperidin-1-ylpropyl) pyridine-3-carboxylate Chemical compound C1CCCCN1CC(O)COC(=O)C1=CC=CN=C1 LEAWDHURBAHMCQ-UHFFFAOYSA-N 0.000 claims description 17
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 16
- 206010022489 Insulin Resistance Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 229960003105 metformin Drugs 0.000 claims description 10
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 9
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 7
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 5
- 229960004844 lovastatin Drugs 0.000 claims description 5
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 5
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 5
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 4
- 229960004580 glibenclamide Drugs 0.000 claims description 4
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 229960002855 simvastatin Drugs 0.000 claims description 4
- 229940125708 antidiabetic agent Drugs 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 3
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 claims description 2
- 239000012050 conventional carrier Substances 0.000 claims description 2
- 208000011661 metabolic syndrome X Diseases 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000011570 nicotinamide Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 8
- -1 biphenylyl Chemical group 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 5
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- HPYLZSUEFFQHRS-UHFFFAOYSA-N 2h-1,2,4-oxadiazine Chemical compound N1OC=CN=C1 HPYLZSUEFFQHRS-UHFFFAOYSA-N 0.000 abstract 1
- YOGBMCNYVFIMJS-UHFFFAOYSA-N 5,6-dihydro-2h-1,2,4-oxadiazine Chemical compound C1CON=CN1 YOGBMCNYVFIMJS-UHFFFAOYSA-N 0.000 abstract 1
- 125000002723 alicyclic group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000002402 anti-lipaemic effect Effects 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 19
- 239000008103 glucose Substances 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 238000001802 infusion Methods 0.000 description 7
- ISGGVCWFTPTHIX-UHFFFAOYSA-N n'-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide;dihydrochloride Chemical compound Cl.Cl.C1CCCCN1CC(O)CONC(=N)C1=CC=CN=C1 ISGGVCWFTPTHIX-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 230000000260 hypercholesteremic effect Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- WLAMNBDJUVNPJU-BYPYZUCNSA-N 2-Methylbutanoic acid Natural products CC[C@H](C)C(O)=O WLAMNBDJUVNPJU-BYPYZUCNSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (27)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0202204A HU226244B1 (hu) | 2002-07-05 | 2002-07-05 | Gyógyszer-kombináció a diabétesz megelõzésére vagy kezelésére |
| CNB02814340XA CN1270713C (zh) | 2001-07-17 | 2002-07-10 | 一种用于预防或治疗糖尿病的协同药物组合物 |
| AT02751454T ATE386523T1 (de) | 2001-07-17 | 2002-07-10 | Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes |
| BR0210744-9A BR0210744A (pt) | 2001-07-17 | 2002-07-10 | Combinação farmacêutica sinergìstica para a prevenção ou tratamento de diabetes |
| EP02751454A EP1408966B1 (en) | 2001-07-17 | 2002-07-10 | Synergistic pharmaceutical combinations for the prevention or treatment of diabetes |
| JP2003513558A JP4598390B2 (ja) | 2001-07-17 | 2002-07-10 | 糖尿病予防、または糖尿病治療のための相乗作用の薬学的組成物 |
| PCT/HU2002/000067 WO2003007951A1 (en) | 2001-07-17 | 2002-07-10 | A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| PT02751454T PT1408966E (pt) | 2001-07-17 | 2002-07-10 | Combinações farmacêuticas sinergísticas para a prevenção ou tratamento da diabetes |
| AU2002354884A AU2002354884B2 (en) | 2001-07-17 | 2002-07-10 | A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| US10/495,240 US7635674B2 (en) | 2001-07-17 | 2002-07-10 | Synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| IL15941202A IL159412A0 (en) | 2001-07-17 | 2002-07-10 | A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| SI200230685T SI1408966T1 (sl) | 2001-07-17 | 2002-07-10 | Sinergistične farmacevtske kombinacije za preprečevanje ali zdravljenje diabetesa |
| ES02751454T ES2300460T3 (es) | 2001-07-17 | 2002-07-10 | Combinaciones farmaceuticas sinergicas destinadas a la prevencion o al tratamiento de la diabetes. |
| CA002682251A CA2682251A1 (en) | 2001-07-17 | 2002-07-10 | A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| PL364662A PL205826B1 (pl) | 2001-07-17 | 2002-07-10 | Synergistyczna kombinacja farmaceutyczna do zapobiegania lub leczenia cukrzycy i zastosowanie |
| CA002452558A CA2452558C (en) | 2001-07-17 | 2002-07-10 | A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| DK02751454T DK1408966T3 (da) | 2001-07-17 | 2002-07-10 | Synergistiske farmaceutiske kombinationer til forebyggelse eller behandling af diabetes |
| RU2004105149/15A RU2311907C2 (ru) | 2001-07-17 | 2002-07-10 | Синергичный фармацевтический состав для профилактики или лечения диабета |
| MXPA04000324A MXPA04000324A (es) | 2001-07-17 | 2002-07-10 | Una combinacion farmaceutica sinergistica para la prevencion o tratamiento de diabetes. |
| DE60225143T DE60225143T2 (de) | 2001-07-17 | 2002-07-10 | Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes |
| KR1020047000748A KR100920560B1 (ko) | 2001-07-17 | 2002-07-10 | 당뇨병을 예방하거나 치료하기 위한 상승작용성 약제학적배합물 |
| UA2004021166A UA81608C2 (ru) | 2002-07-05 | 2002-07-10 | Синергическая фармацевтическая комбинация для профилактики или лечения диабета |
| NZ531155A NZ531155A (en) | 2001-07-17 | 2002-07-10 | A synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| IL159412A IL159412A (en) | 2001-07-17 | 2003-12-17 | Synergistic pharmaceutical combination for the prevention or treatment of diabetes |
| NO20040153A NO20040153L (no) | 2001-07-17 | 2004-01-13 | Synergistisk farmasoytisk kombinasjon for profylakse eller behandling av diabetes |
| CY20081100487T CY1107939T1 (el) | 2001-07-17 | 2008-05-08 | Συνεργικοι φαρμακευτικοι συνδυασμοι για την προληψη ή την αγωγη του διαβητη |
| US12/614,225 US8048873B2 (en) | 2001-07-17 | 2009-11-06 | Synergistic pharmaceutical combination for the prevention or treatment of diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0202204A HU226244B1 (hu) | 2002-07-05 | 2002-07-05 | Gyógyszer-kombináció a diabétesz megelõzésére vagy kezelésére |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HU0202204D0 HU0202204D0 (enExample) | 2002-09-28 |
| HUP0202204A2 HUP0202204A2 (en) | 2003-05-28 |
| HU226244B1 true HU226244B1 (hu) | 2008-07-28 |
Family
ID=89980598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0202204A HU226244B1 (hu) | 2001-07-17 | 2002-07-05 | Gyógyszer-kombináció a diabétesz megelõzésére vagy kezelésére |
Country Status (2)
| Country | Link |
|---|---|
| HU (1) | HU226244B1 (enExample) |
| UA (1) | UA81608C2 (enExample) |
-
2002
- 2002-07-05 HU HU0202204A patent/HU226244B1/hu not_active IP Right Cessation
- 2002-07-10 UA UA2004021166A patent/UA81608C2/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0202204A2 (en) | 2003-05-28 |
| UA81608C2 (ru) | 2008-01-25 |
| HU0202204D0 (enExample) | 2002-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040242634A1 (en) | Methods for treating prion diseases | |
| US7834056B2 (en) | Pharmaceutical composition for gout | |
| KR20010032906A (ko) | 고위험의 내당력 장애를 치료하기 위한 알파-글루코시다제억제제의 용도 | |
| CZ187097A3 (cs) | Farmaceutický prostředek | |
| SK78395A3 (en) | Combination of a cholesterol biosythesis ihibitor and beta-lactam cholesterol absorption inhibitor and use of it | |
| SK287287B6 (sk) | Farmaceutická kompozícia obsahujúca pioglitazón a metformín | |
| US11911382B2 (en) | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension | |
| US7094797B2 (en) | Organ fibrosis inhibitor | |
| EP1408966B1 (en) | Synergistic pharmaceutical combinations for the prevention or treatment of diabetes | |
| KR20050044772A (ko) | 안정적인 경구용 고형 의약 조성물 | |
| KR20010113537A (ko) | 전신 홍반성낭창 및 염증성 장 질환을 치료하기 위한 성장호르몬 분비촉진제의 용도 | |
| US5616618A (en) | Threo-3-(3,4-dihydroxyphenyl)serine analgesic composition | |
| CZ285633B6 (cs) | Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek | |
| CN1777417B (zh) | PPARα激动剂和二甲双胍降低血清甘油三酯的用途 | |
| EP4331583A1 (en) | Blood carnitine-increasing agent | |
| KR100310665B1 (ko) | 피부질환치료용약제학적조성물 | |
| EP1243261B1 (en) | Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia | |
| US6451799B1 (en) | Drugs for ameliorating ocular circulatory disorders | |
| RU2061481C1 (ru) | Средство, обладающее антиагрегационной активностью | |
| KR100895031B1 (ko) | 지질 농후 플라크의 감소, 안정화 및 파열 방지 방법 | |
| US5486506A (en) | Method for treating cardiac inotropic irregularities | |
| JP6976577B2 (ja) | ＰＰＡＲαアゴニストを含有する、肺高血圧症の予防又は治療剤 | |
| JP2835547B2 (ja) | 糖尿病治療剤 | |
| US20040242485A1 (en) | Compositions and methods for the amelioration of leptin resistance | |
| US20060009475A1 (en) | Quinazolinone compounds in combined modalities for improved cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NF4A | Restoration of patent protection | ||
| MM4A | Lapse of definitive patent protection due to non-payment of fees |